Pressmeddelande -
Sortina Pharma Selected for the Brain Tumour Research Novel Therapeutics Accelerator Programme
..............................................................
GU Ventures share news and information about the business, its companies, and alumni companies:
..............................................................
Sortina Pharma, a pioneer in developing next-generation therapies for cancer proudly announces its selection for the prestigious Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA) programme. This international initiative, launched by the Tessa Jowell Brain Cancer Mission (TJBCM) in partnership with Brain Tumour Research in 2023, provides independent expert guidance to de-risk and accelerate the development of novel brain tumour therapies.
Sortina Pharma’s lead oncology drug candidate, which targets Glioblastoma will benefit from up to 240 hours of expert consultation through the BTR-NTA programme. This support will help refine the development strategy, strengthen preclinical and clinical trial planning, and optimize regulatory and commercialization pathways.
“We are honored to be selected for the BTR-NTA programme,” says Sara Rhost, CEO and co-founder of Sortina Pharma. “This opportunity provides invaluable access to global experts who will help us advance our lead candidate towards clinical proof of concept. GBM remains one of the most aggressive and challenging brain cancers to treat, and we are committed to developing innovative solutions that can make a real difference for patients.”
The BTR-NTA programme is designed to support both academic and industry researchers in navigating the complexities of translational brain tumour research, including regulatory challenges, clinical trial design, and commercialization strategies. Since its launch, the initiative has supported numerous international projects, helping accelerate breakthrough treatments in neuro-oncology.
Sortina Pharma’s participation in BTR-NTA aligns with its broader mission to develop world-class targeted therapies for cancers with high unmet medical needs. The company’s strong intellectual property position, covering chemical structures, further strengthens its potential for strategic partnerships and future commercialization.
About Sortina Pharma
Sortina Pharma is a pre-clinical drug development company founded in 2020 based on research originating from professor Göran Landberg´s research group at Gothenburg University, Sweden. The company develops anti-Sortilin small molecule inhibitors as well-tolerated oral treatment for cancer patients, with or at risk of recurrencies and metastases, aiming to increase survival rates of incurable Sortilin positive cancers such as Glioblastoma, Breast Cancer, Melanoma and Pancreatic Cancer.
For more information, please visit: https://www.sortinapharma.com/
For more information about the Tessa Jowell Brain Cancer Mission (TJBCM) and Brain Tumour Research, please visit their respective websites:
https://www.tessajowellbraincancermission.org/
Ämnen
Kategorier
About GU Ventures AB
GU Ventures builds companies from groundbreaking ideas that can shape a better tomorrow. It is ranked among the world's top 20 university-linked incubators by the UBI Global Index. We finance and develop new innovative business ideas connected to the University of Gothenburg, one of Northern Europe's largest universities. Our mission is to commercialize these innovations, ensuring that research and expertise are utilized to drive business renewal, create jobs, and foster sustainable growth. Our passionate team of company builders, financial experts, IP specialists, and legal professionals is dedicated to supporting our companies and ensuring their success.
Since its inception in 1995, GU Ventures has developed over 240 new business ideas, of which 140 are active today, and 15 are publicly listed. Our portfolio consists of around 80 holdings and several projects.
In the latest survey, 87% of the companies align with the UN's global sustainability goals. GU Ventures is fully owned by the Swedish state and managed by the University of Gothenburg. Learn more at: www.guventures.com.
